News Orgenesis Inc.

Equities

ORGS

US68619K2042

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
0.5009 ^USD	-2.19%		+1.60%	+0.04%

Apr. 16	North American Morning Briefing : Powell Comments, -2-	DJ
Apr. 15	Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Powell Comments, -2-	Apr. 16	DJ
Orgenesis Provides Year End Business Update	Apr. 15	AQ
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
Orgenesis : Non-Reliance on Previously Issued Financial Report - Form 8-K	Apr. 15	PU
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility	Apr. 10	AQ
Germfree and Orgenesis Inc. Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility	Apr. 10	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference	Mar. 18	AQ
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes	Mar. 13	AQ
Orgenesis Inc. announced that it has received $2.340901 million in funding	Mar. 04	CI
Orgenesis Inc. Announces $2.3 Million Private Placement	Mar. 04	AQ
Orgenesis Inc. announced that it expects to receive $2.340901 million in funding	Mar. 02	CI
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing	Feb. 29	AQ
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic	Jan. 31	AQ
Orgenesis Inc. agreed to acquire 25% stake in Octomera LLC from MM OS Holdings, L.P.	Jan. 30	CI
Orgenesis Inc. entered into a binding Term Sheet agreement to acquire Octomera LLC from MM OS Holdings, L.P.	Jan. 23	CI
Alimera Sciences Appoints New CFO	Jan. 02	MT
Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM	Nov. 14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Orgenesis Inc.

Equities

ORGS

US68619K2042

Summary

Filters